Cannabidiol is one of many (probably 200) cannabis plant compounds.At its October 2016 conference, the WHO Expert Committee on Drug Dependence decided that, in its pure form, cannabidiol does not appear to have any potential for injury or harm to fitness. As cannabidiol is currently not classified as a substance in its own right (only as cannabis extracts), current information does not warrant a change of status or classification of this substance.
However, to the extent that CBD is produced for pharmaceutical purposes as a cannabis extract, cannabis extracts and tinctures are included in the United Nations Single Convention on Narcotic Drugs, 1961. Selections or compounds containing almost mainly CBD will be further explored in June 2018, when the WHO Expert Committee will bring out a thorough analysis of cannabis and related materials.
The non-classification of a substance means that it is not placed under strict international control, including for production and supply. The definition of its legal status in the countries is the responsibility of national legislators. Some states have relaxed cannabidiol regulations to consider products containing them as medical products. These include Australia, Canada, the United States of America, the United Kingdom, and Switzerland.
What is the evidence that cannabidiol is useful for medical purposes?
WHO does not recommend the use of cannabidiol for medical purposes? The first data from studies in humans and animals (a controlled study published in the New England Journal of Medicine and other individual cases reported) show that its use could have therapeutic benefits for seizures due to epilepsy and associated pathologies.
Cannabidiol (CBD) update on legislation
Many products sponsored as including CBD have recently emerged on the French market. MILDECA led an inter-ministerial performance group to make current legal and technical report validated by all applicable authorities.
Cannabidiol (CBD) is one of the primary active compounds of cannabis, otherwise known as hemp, as is delta-9-tetrahydrocannabinol (THC). Tetrahydrocannabinol is substances on the Narcotic List 3. Their use is, therefore, strictly regulated.
Several products shown as containing CBD have recently developed on the world market. These are necessarily e-liquids for electronic cigarettes, cosmetics, or capsules.
Therefore, health authorities wish to clarify the regulations applicable to these products.
The French legislation provides that all transactions involving cannabis are prohibited, including its production, possession, and use of 1. Therefore, any product containing cannabidiol extracted from the cannabis plant is not permitted unless it falls within the scope of the derogation mentioned below.
This derogation from this prohibition principle exists to allow the use of hemp for industrial and commercial purposes, in particular in the textile, automobile, building, paper, poultry, and garment industries: fishing, cosmetics, food, and gardening.
Thus, specific varieties of cannabis or hemp, devoid of stupefying properties, can be used for industrial and commercial purposes under three cumulative conditions:
- the authorized varieties of hemp are on a list 2 ;
- Only seeds and fibers can be used. The use of flowers is forbidden;
- The plant must have a content of less than 0.2% THC.
However, controls carried out in some products presented as containing CBD revealed the presence of THC.
Some people use cannabidiol to calm spasms during epileptic seizures. Recently, the New England Journal of Medicine has also published a study indicating that there is evidence of possible efficacy during epileptic seizures. This means that it could be used for medical purposes, but other evidence is still needed. Have you more information and medication you can Visit the CBD Cannabidiol site Link.